Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and progressive form of pulmonary hypertension (PH) caused by blood clots that don’t dissolve in the lungs. These clots cause scar-like tissue that clogs up or narrows the small blood vessels in the lungs. The surgical and medical treatment options for CTEPH and their limitations are discussed in this touchRESPIRATORY interview with Dr Gustavo Heresi (Cleveland Clinic, Cleveland, OH, USA) as well as future emerging therapies.
The presentation titled ‘CTEPH – Overview and Treatments’ was presented at the Pulmonary Hypertension Association, June 10-12, 2022
Questions
- What are the surgical and medical treatment options and what are their limitations?
- What are the challenges in the future development of medical therapy for CTEPH?
- What are the most exciting emerging therapies for CTEPH?
Disclosures: Gustavo Heresi discloses grant/research support from Bayer Healthcare.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the PHA Hybrid Congress 2022.
